Yasaman Setayeshpour

Ms. Yasaman Setayeshpour

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CLChao-Chieh Lin
Chao-Chieh Lin
YLYi-Tzu Lin
Yi-Tzu Lin
SCSsu-Yu Chen
Ssu-Yu Chen
YSYasaman Setayeshpour
Yasaman Setayeshpour
YCYubin Chen
Yubin Chen
JCJen-Tsan Ashley Chi
Jen-Tsan Ashley Chi
The cystine-xCT transporter/glutathione/GPX4 axis is the canonical pathway protecting cells from ferroptosis. Whereas GPX4-targeting ferroptosis-inducing compounds (FINs) act independently of mitochondria, xCT-targeting FINs require mitochondrial lipid peroxidation, though the mechanism remains unclear. Because cysteine is also a precursor for coenzyme A (CoA) biosynthesis, here, we demonstrated that CoA supplementation selectively prevented ferroptosis triggered by xCT inhibition by regulating the mitochondrial thioredoxin system. Our data showed that CoA regulated the in vitro enzymatic activity of mitochondrial thioredoxin reductase-2 (TXNRD2) by covalently modifying the thiol group of cysteine (CoAlation) on Cys-483. Replacing Cys-483 with alanine on TXNRD2 abolished its enzymatic activity and ability to protect cells against ferroptosis. Targeting xCT to limit cysteine import and, therefore, CoA biosynthesis reduced CoAlation on TXNRD2. Furthermore, the fibroblasts from patients with disrupted CoA metabolism had increased mitochondrial lipid peroxidation. In organotypic brain slice cultures, inhibition of CoA biosynthesis led to an oxidized thioredoxin system, increased mitochondrial lipid peroxidation, and loss of cell viability, which were all rescued by ferrostatin-1. These findings identified CoA-mediated posttranslational modification to regulate the thioredoxin system as an alternative ferroptosis protection pathway with potential clinical relevance for patients with disrupted CoA metabolism.

29 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
YSYasaman Setayeshpour
Yasaman Setayeshpour
YLYunji Lee
Yunji Lee
JCJen-Tsan Ashley Chi
Jen-Tsan Ashley Chi
Given the enormous suffering and death associated with human cancers, there is an urgent need for novel therapeutic approaches to target tumor growth and metastasis. While initial efforts have focused on the dysregulated oncogenic program of cancer cells, recent focus has been on the modulation and targeting of many “cancer-friendly,” non-genetic tumor microenvironmental factors, which support and enable tumor progression and metastasis. Two prominent examples are anti-angiogenesis and immunotherapy that target tumor-supporting vascularization and the immune-suppressive tumor microenvironment (TME), respectively. Lately, there has been significant interest in the therapeutic potential of ferroptosis, a natural tumor suppression mechanism that normally occurs as a result of oxidative stress, iron imbalance, and accumulation of lipid peroxides. While numerous studies have identified various cell intrinsic mechanisms to protect or promote ferroptosis, the role of various TME stress factors are also recently recognized to modulate the tumor cells’ susceptibility to ferroptosis. This review aims to compile and highlight evidence of these factors, how various TME stresses affect ferroptosis, and their implications in various stages of tumor development and expected response to ferroptosis-triggering therapeutics under development. Consequently, understanding ways to enhance ferroptosis sensitivity both intracellularly and in the TME may optimize therapeutic sensitivity to minimize or prevent tumor growth and metastasis.

11 May 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
YSYasaman Setayeshpour
Yasaman Setayeshpour
SCSsu-Yu Chen
Ssu-Yu Chen
DDDivya L. Dayanidhi
Divya L. Dayanidhi
YLYunji Lee
Yunji Lee
SWShao-Chin Wu
Shao-Chin Wu
JCJen-Tsan Ashley Chi
Jen-Tsan Ashley Chi
The peritoneum is a frequent site of metastasis in ovarian cancer (OVCA), often accompanied by the accumulation of ascites in the peritoneal cavity. Despite its prevalence, ascites and its role in the peritoneal growth of OVCA remain poorly understood. OVCA cells are vulnerable to ferroptosis, a type of cell death caused by lipid hydroperoxides, raising the question of how these ferroptosis-sensitive cells survive during metastasis. Here, we show that ascites from female donors protects OVCA cell lines, patient-derived tumor cells, and organoids against ferroptosis and enhances peritoneal tumor growth in female mice. Mechanistically, ascites downregulates 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), contributing to increased lipid droplets. Additionally, upon ferroptosis induction, ascites represses upregulation of the transferrin receptor TFRC, thereby decreasing labile iron levels. Furthermore, lipid-lowering fibrates reverse ascites-induced changes and attenuate peritoneal growth in female mice. These findings identify ascites-mediated ferroptosis protection as a key mechanism in OVCA metastasis and a potential therapeutic vulnerability.

25 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
YSYasaman Setayeshpour
Yasaman Setayeshpour
SCSsu-Yu Chen
Ssu-Yu Chen
DDDivya L. Dayanidhi
Divya L. Dayanidhi
YLYunji Lee
Yunji Lee
CFChiara Federico
Chiara Federico
JCJen-Tsan Ashley Chi
Jen-Tsan Ashley Chi
One of the most common sites of metastasis in ovarian cancer (OVCA) is the peritoneum. Often, this spread is accompanied by the accumulation of a fluid called ascites in the peritoneal cavity. Despite its common occurrence in metastatic OVCA patients, ascites and its influence on the peritoneal spread of OVCA are poorly understood. Interestingly, OVCA cells are vulnerable to ferroptosis, a type of cell death caused by lipid peroxidation. Hence, how these ferroptosis-sensitive OVCA cells persist in their spread to the peritoneum remains unknown. Here, we show that ascites robustly protects OVCA cells and patient-derived organoids against ferroptosis and enhances the peritoneal spread of OVCA cells in mice. Mechanistically, ascites downregulates the mitochondrial enzyme, 3-hydroxy-3-methylglutaryl-CoA synthase 2 ( HMGCS2 ), which contributes to an increase in lipid droplets. Additionally, upon ferroptosis induction, ascites represses the upregulation of the transferrin receptor, TFRC , thereby decreasing cellular labile iron levels. Furthermore, we show that lipid-lowering fibrates reverse cellular changes induced by ascites, and they attenuate the peritoneal spread of OVCA cells in mice. Our findings implicate the importance of ascites in ferroptosis protection and the peritoneal spread of OVCA, and they suggest that targeting the ferroptosis protection by ascites may present a novel therapeutic approach to limit OVCA metastasis.

10 April 2026 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
CLChao-Chieh Lin
Chao-Chieh Lin
JRJoshua Rose
Joshua Rose
AZAlbert Zhang
Albert Zhang
AMAnthony J. Mirando
Anthony J. Mirando
AMAlexander A. Mestre
Alexander A. Mestre
JCJen-Tsan Ashley Chi
Jen-Tsan Ashley Chi

20 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAlexander A. Mestre
Alexander A. Mestre
YOYunju Oh
Yunju Oh
JWJianli Wu
Jianli Wu
DDDenise Dunn
Denise Dunn
YSYasaman Setayeshpour
Yasaman Setayeshpour
JCJen-Tsan Ashley Chi
Jen-Tsan Ashley Chi
Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation and contributes to diverse pathologies including ischemia-reperfusion injury and neurodegenerative disorders. Current ferroptosis inhibitors largely function as nonspecific radical-trapping antioxidants, limiting their clinical utility. We previously identified MESH1 as a key regulator of ferroptosis through its NADPH phosphatase activity. Here, we identify 4,5,6,7-tetrabromo-1 H -benzotriazole (TBB) as a small molecule inhibitor of MESH1 with an IC 50 value of 4.7 ± 0.3 µM. X-ray crystallography revealed the molecular determinants of TBB recognition which are corroborated through structure-activity relationships of TBB analogs. TBB protected multiple cell lines against ferroptosis in vitro , and this effect was mitigated by MESH1 knockdown, consistent with on-target activity. Furthermore, TBB reduced neuronal death in an ex vivo brain slice model of Alzheimer’s disease. Collectively, these findings establish TBB as a bona fide small-molecule MESH1 inhibitor that suppresses ferroptosis and establishes MESH1 as a promising therapeutic target. Graphical Depicting mechanism of TBB suppressing ferroptosis through the inhibition of MESH1. Figure Created with Biorender.com